Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04271956 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04271956 · ClinicalTrials.gov record · last posted 2026-08-20

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation

Name: Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation — clinical trial record (NCT04271956)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CLL-RT1

StatusRecruiting

PhasePhase 2

SponsorGerman CLL Study Group

Started2020-02-19

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

Protocol amendment history 2 changes detected by DataLookout

2026-08-21

Primary completion pushed: 2026-08 → 2027-08

2026-08-21

Completion pushed: 2026-08 → 2027-08

Trial Details

NCT Number	NCT04271956
Lead Sponsor	German CLL Study Group
Conditions	Richter Transformation
Enrollment	83 participants
Start Date	2020-02-19
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-20